Merck's cancer therapy mAb under regulatory review in Europe


The European Medicines Agency accepts Merck's (MRK) MAA for pembrolizumab, the firm's investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved, it will be the first anti-PD-1 therapy cleared for sale in Europe.

Pembrolizumab is a humanized monoclonal anti-PD-1 antibody designed to reactivate anti-tumor immunity. It blocks the PD-1 pathway by inhibiting the interaction of PD-1 on T cells with its ligands PD-L1 and PD-L2.

It is being evaluated across more than 30 types of cancers as a monotherapy and in combination. The company's BLA is currently under priority review by the FDA with a PDUFA date of October 28, 2014. The agency designated it a Breakthrough Therapy for advanced melanoma.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs